Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T

Trial Details

NCT ID
NCT07218315
Phase
NA
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Papillary Thyroid Cancer
Interventions
  • CellFX nsPFA Percutaneous Electrode System
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participant must provide voluntary, written informed consent to participate in this clinical investigation.
  • Participant agrees to comply with all study procedures, including all follow-up visits.
  • Participant with a Bethesda VI cytology (tumor size \<= 1.5 cm, no known regional/distant metastases)
  • Participant with a Bethesda V cytology and normal calcitonin levels.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Papillary Thyroid Cancer Trials on Trialify →